MYD88

Across TCGA pan-cancer cohorts, MYD88 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYD88 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MYD88 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYD88 expression acts as an unfavorable survival marker.

MESO, DLBC, and PRAD are the cancer types where MYD88 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
DLBC	OS	Median	II,III,IV	0.586	0.949	.014	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYD88–MESO (OS)

Open the MESO breakdown →